Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 5Unknown 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Melanoma 2Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cytarabine 55Decitabine 33Azacitidine 30Idarubicin 22venetoclax 21fludarabine 16Cyclophosphamide 16Granulocyte Colony-Stimulating Factor 15Daunorubicin 12Mitoxantrone 9Etoposide 8Cladribine 8Busulfan 8Aclarubicin 8Homoharringtonine 7Filgrastim 7Peripheral Blood Stem Cell Transplantation 6fludarabine phosphate 5aclacinomycins 4Tretinoin 4Sorafenib 4Radiotherapy 4Polymerase Chain Reaction 4Mycophenolic Acid 4Lenalidomide 4Gemtuzumab 4Cyclosporine 4Clofarabine 4Arsenic Trioxide 4sargramostim 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Leukemia, Myeloid, Acute × guadecitabine × Clear all
NCT03454984 2018-11-15

SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation

Groupe Francophone des Myelodysplasies

Phase 2 Unknown
40 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡